Asia-Pacific Journal of Clinical Oncology

Asia-Pacific Journal of Clinical Oncology

ASIA-PAC J CLIN ONCO
影响因子:1.6
是否综述期刊:
是否预警:不在预警名单内
是否OA:
出版国家/地区:AUSTRALIA
出版社:Wiley-Blackwell Publishing Ltd
发刊时间:2005
发刊频率:Quarterly
收录数据库:SCIE/Scopus收录
ISSN:1743-7555

期刊介绍

Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.
《亚太临床肿瘤学杂志》是一本多学科肿瘤学杂志,旨在成为一个论坛,促进亚太地区不同国家在癌症治疗和护理方面的合作和信息交流。该杂志是理想的定位,以接收出版物,处理多样性的癌症行为,管理和结果有关的种族,文化,经济和其他差异之间的人口。除了原创文章外, 《日刊》还发表评论、社论、致编辑的信和简短通讯。病例报告通常不考虑发表,只有编辑发现具有非凡肿瘤学价值的例外论文才考虑进行审查。该杂志鼓励临床研究,特别是前瞻性设计的临床试验。
年发文量 69
国人发稿量 17.69
国人发文占比 0.26%
自引率 -
平均录取率0
平均审稿周期 较慢,6-12周
版面费 US$3250
偏重研究方向 医学-肿瘤学
期刊官网 http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1743-7563
投稿链接 https://mc.manuscriptcentral.com/apjco

期刊高被引文献

Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection
来源期刊:Asia-Pacific Journal of Clinical OncologyDOI:10.1111/ajco.13050
A prognostic nomogram constructed for relapsed or refractory diffuse large B-cell lymphoma patients.
来源期刊:Asia-Pacific journal of clinical oncologyDOI:10.1111/ajco.13222
Stereotactic body radiation therapy for oligometastatic pulmonary tumors from cervical cancer
来源期刊:Asia-Pacific Journal of Clinical OncologyDOI:10.1111/ajco.13159
A phase I/II trial of weekly nab‐paclitaxel for pretreated non‐small‐cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement
来源期刊:Asia-Pacific Journal of Clinical OncologyDOI:10.1111/ajco.13147
When compared to plasma-based detection, osimertinib-treated non-small cell lung cancer (NSCLC) with tissue rebiopsy-confirmed acquired T790M mutation is associated with better survival.
来源期刊:Asia-Pacific journal of clinical oncologyDOI:10.1111/ajco.13287
Phase II APEC trial: The impact of primary tumor side on outcomes of first‐line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild‐type metastatic colorectal cancer
来源期刊:Asia-Pacific Journal of Clinical OncologyDOI:10.1111/ajco.13154
A multicenter observational study of the real‐world use of docetaxel for metastatic castration‐resistant prostate cancer in China
来源期刊:Asia-Pacific Journal of Clinical OncologyDOI:10.1111/ajco.13142
Androgen deprivation therapy in nonmetastatic prostate cancer patients: Indications, treatment effects, and new predictive biomarkers
来源期刊:Asia-Pacific Journal of Clinical OncologyDOI:10.1111/ajco.13108
Axillary dissection in sentinel lymph node positive breast cancer: Is the staging information worthwhile for patients?
来源期刊:Asia-Pacific journal of clinical oncologyDOI:10.1111/ajco.13238
Cost-effective analysis of supervised exercise training in men with prostate cancer previously treated with androgen deprivation therapy and radiation
来源期刊:Asia-pacific Journal of Clinical OncologyDOI:10.1111/AJCO.13262
Partial chest wall radiation therapy for positive or close surgical margins after modified radical mastectomy for breast cancer without lymph node metastasis
来源期刊:Asia-Pacific Journal of Clinical OncologyDOI:10.1111/ajco.13276
Improved gut integrity in female breast cancer survivors after a 12-week exercise intervention
来源期刊:Asia-pacific Journal of Clinical OncologyDOI:10.1111/AJCO.13263

质量指标占比

研究类文章占比 OA被引用占比 撤稿占比 出版后修正文章占比
84.06%23.78%--

相关指数

影响因子
影响因子
年发文量
自引率
Cite Score

预警情况

查看说明
时间 预警情况
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
*来源:中科院《 国际期刊预警名单》

JCR分区

WOS分区等级:Q4区
版本 按学科 分区
WOS期刊SCI分区
WOS期刊SCI分区
WOS期刊SCI分区是指SCI官方(Web of Science)为每个学科内的期刊按照IF数值排 序,将期刊按照四等分的方法划分的Q1-Q4等级,Q1代表质量最高,即常说的1区期刊。
(2024-2025年最新版)
ONCOLOGY
Q4

中科院分区

查看说明
版本 大类学科 小类学科 Top期刊 综述期刊
2025年3月最新升级版
医学4区
ONCOLOGY 肿瘤学
4区
2023年12月升级版
医学4区
ONCOLOGY 肿瘤学
4区
2022年12月旧的升级版
医学4区
ONCOLOGY 肿瘤学
4区